Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Assets: 2010-2025

Historic Assets for Ligand Pharmaceuticals (LGND) over the last 15 years, with Sep 2025 value amounting to $1.5 billion.

  • Ligand Pharmaceuticals' Assets rose 54.66% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 54.66%. This contributed to the annual value of $941.8 million for FY2024, which is 19.63% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Assets stood at $1.5 billion, which was up 55.68% from $948.6 million recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Assets peaked at $1.5 billion during Q3 2025, and registered a low of $758.1 million during Q2 2023.
  • Its 3-year average for Assets is $921.2 million, with a median of $905.4 million in 2025.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Assets crashed by 41.22% in 2022, and later soared by 54.66% in 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Assets (Quarterly) stood at $1.3 billion in 2021, then slumped by 41.22% to $762.7 million in 2022, then increased by 3.22% to $787.2 million in 2023, then grew by 19.63% to $941.8 million in 2024, then surged by 54.66% to $1.5 billion in 2025.
  • Its Assets stands at $1.5 billion for Q3 2025, versus $948.6 million for Q2 2025 and $905.4 million for Q1 2025.